Table 2.
Treatment effect and effect size in the HAMD-17 and MADRS total score estimated using the propensity weighed and non-weighted analyses.
| Study SEP360-029 | Comparison | TE | StdErr | P* | SD | Effect_size |
|---|---|---|---|---|---|---|
| Reference | Pbo vs. Dasotr. 0.5 mg | 0.236 | 0.985 | 1.000 | 7.818 | 0.030 |
| Pbo vs. Dasotr. 2.0 mg | −0.466 | 0.981 | 1.000 | 7.849 | 0.059 | |
| Pbo vs. Venlafax. 150 mg | 4.104 | 1.015 | 0.0094 | 7.990 | 0.514 | |
| Propensity | Pbo vs. Dasotr. 0.5 mg | 3.008 | 0.916 | 0.115 | 7.273 | 0.414 |
| Analysis | Pbo vs. Dasotr. 2.0 mg | 2.718 | 0.953 | 0.324 | 7.620 | 0.357 |
| Pbo vs. Venlafax. 150 mg | 6.928 | 0.958 | <0.0001 | 7.543 | 0.918 |
| Study SEP380-201 | Comparison | TE | StdErr | p* | SD | Effect_size |
|---|---|---|---|---|---|---|
| Reference | Pbo vs. Amisulp. 200 mg | 3.411 | 1.619 | 0.6188 | 11.336 | 0.301 |
| Pbo vs. Amisulp. 400 mg | 3.280 | 1.592 | 0.6513 | 11.170 | 0.294 | |
| Propensity | Pbo vs. Amisulp. 200 mg | 6.504 | 1.315 | <0.0001 | 9.208 | 0.706 |
| Analysis | Pbo vs. Amisulp. 400 mg | 7.151 | 1.325 | <0.0001 | 9.295 | 0.769 |
TE treatment effect, StdErr standard error, P probability, SD standard deviation.
*P-value adjusted for multiplicity.